Telo Genomics Corp.

OTC: TDSGF · Healthcare · Medical - Diagnostics & Research

Canadian filerHQ Toronto, ONReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 20DQ —GM —SS 28

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, disclosure history · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.9M

Employees

Market cap

$2.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$1.9M-2.7M CAD2025

Operating income-$1.9M-2.7M CAD2025

Total assets$490.6k669.3k CAD2025

Liabilities$213.4k291.1k CAD2025

Equity$377.5k515.0k CAD2025

Revenue trend

FY2017 – FY2025 · USD

FY17

FY18

FY19

FY20

FY21

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Telo Genomics Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Bio Green Med Solution, Inc.47D VitaSpring Biomedical Co. Ltd.18D Digital Commodities Inc.52D PMGC Holdings Inc.28D

Key facts

CEOJohn Allen Farlinger

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersToronto, ON

ExchangeOTC: TDSGF

Employees8

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.